According to the 2015 ESC/ERS guidelines on pulmonary hypertension, the overall treatment goal in patients with PAH is to achieve or maintain a low-risk status, which is usually associated with good exercise capacity, good quality of life, good right ventricle function and a low mortality risk. Patients at low risk have been shown to have the best outcomes.
Regular comprehensive risk assessment of PAH patients is recommended to evaluate patients’ risk status and escalate therapy if required.
WORLD SYMPOSIUM ON PULMONARY HYPERTENSION
Advice on how to manage your UPTRAVI® patients, including details on dosage and side effects.
A synopsis of the key benefits of UPTRAVI® in the treatment of PAH.